Prescription medication · Azole Antifungal
isavuconazonium
Also sold as Cresemba. Cresemba treats invasive aspergillosis and invasive mucormycosis.
Data updated 2026-05-15
- 3,219
- FDA reportsLightly reported
- 9
- InteractionsFew interactions
- $107.94
- Brand price (NADAC)
What the data shows
isavuconazonium (Cresemba) is a prescription Azole Antifungal, among the least-reported drugs the FDA tracks (3,219 FDA reports), with 9 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
isavuconazonium (Cresemba) is a prescription Azole Antifungal. Cresemba treats invasive aspergillosis and invasive mucormycosis.
Cresemba is an antifungal medicine. It is used to treat serious fungal infections in adults and children.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$107.94/unit
Generic Available
No
ASTELLAS
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: CRESEMBA 186 MG CAPSULE
Same CMS presentation as the headline brand unit price above (2 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: +0.8% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| January 18, 2024 | $107.12/EA | - | 1 |
| December 18, 2024 | $107.94/EA | +0.8% | 2 |
What it does
Cresemba treats invasive aspergillosis and invasive mucormycosis.
Common side effects
Nausea, Vomiting, Diarrhea
Key warnings
Cresemba can cause serious liver problems.
The sections below are summarized in plain English from isavuconazonium's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Cresemba belongs to a class of drugs called azole antifungals. It works by stopping the growth of the fungi. This helps your body fight off the infection.
Side Effects (from patient reports)
Based on 3,219 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for isavuconazonium, by number of reports
- Death
Death
310 reports
- Nausea
Nausea
143 reports
- Febrile Neutropenia
Febrile Neutropenia
135 reports
- Pyrexia
Pyrexia
125 reports
- Pneumonia 114
Pneumonia
114 reports
- Condition Aggravated 106
Condition Aggravated
106 reports
- Fatigue 101
Fatigue
101 reports
- Diarrhoea 91
Diarrhoea
91 reports
- Dyspnoea 87
Dyspnoea
87 reports
- Drug Interaction 84
Drug Interaction
84 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for isavuconazonium each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where isavuconazonium sits
isavuconazonium has more FDA adverse-event reports than 19% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is isavuconazonium; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 3,219 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2015–2025.
Total Reports
3,219
Reports Mentioning Death
674
20.9% of reports — not proof of cause
Hospitalization Reports
1,032
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | DEATH | 310 |
| 3 | NAUSEA | 143 |
| 4 | FEBRILE NEUTROPENIA | 135 |
| 6 | PYREXIA | 125 |
| 7 | PNEUMONIA | 114 |
| 8 | CONDITION AGGRAVATED | 106 |
| 9 | FATIGUE | 101 |
| 10 | DIARRHOEA | 91 |
| 11 | DYSPNOEA | 87 |
| 12 | DRUG INTERACTION | 84 |
| 13 | VOMITING | 81 |
| 15 | ACUTE KIDNEY INJURY | 70 |
| 16 | SEPSIS | 63 |
| 17 | PLATELET COUNT DECREASED | 59 |
| 18 | ASPERGILLUS INFECTION | 56 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Cresemba can cause serious liver problems. Your doctor will check your liver function before and during treatment. Cresemba can also cause allergic reactions. Tell your doctor right away if you have any signs of a reaction, like trouble breathing or skin rash. Cresemba can harm an unborn baby. Use birth control while taking this medicine.
Known Drug Interactions
Antihelminthics, Antifungals and Antiprotozoals Isavuconazonium Contraindicated during and 2 weeks after itraconazole treatment.
Mechanism: Itraconazole blocks the body's ability to break down isavuconazonium, which can cause the drug to reach unsafe levels.
Atorvastatin Use with Caution Caution should be used when atorvastatin is used with CRESEMBA due to a potential increase in atorvastatin exposure. Monitor patients for adverse reactions that are typical of atorvastatin [see Clinical Pharmacology ( 12.3 )] .
Mechanism: Isavuconazonium can increase the amount of atorvastatin in your blood by slowing down how your body processes it. This can make you more likely to experience side effects from the cholesterol medicine.
Bupropion Use with Caution Concomitant administration of CRESEMBA and bupropion results in decrease in bupropion exposure. Dose increase of bupropion may be necessary when coadministered with CRESEMBA, but should not exceed the maximum recommended dose [see Clinical Pharmacology ( 12.3 )] .
Mechanism: Taking isavuconazonium can lower the amount of bupropion in your system, making the medication less effective. This happens because the body clears the drug faster than normal.
Cyclosporine Use with Caution Concomitant administration of CRESEMBA and cyclosporine results in increase in cyclosporine exposure. Monitor drug concentrations of cyclosporine and adjust dose as needed [see Clinical Pharmacology ( 12.3 )] . ( 7 ) • Appropriate therapeutic drug monitoring and dose adjustment of immunosuppressants (i.e., tacrolimus, sirolimus, and cyclosporine) may be necessary when coadministered with CRESEMBA.
Mechanism: Isavuconazonium causes cyclosporine to build up in your body by slowing its removal. This can lead to higher levels of the drug, which may cause harm.
Midazolam Use with Caution Concomitant administration of CRESEMBA and midazolam results in increase in midazolam exposure. Consider dose reduction of midazolam when isavuconazole is coadministered [see Clinical Pharmacology ( 12.3 )] .
Mechanism: Isavuconazonium slows down the breakdown of midazolam, which leads to higher levels of the sedative in your blood. This can make the drug's effects much stronger or last longer than intended.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I tell my doctor before taking Cresemba?
Can I take other medicines with Cresemba?
How long will I need to take Cresemba?
What if I have infusion-related reactions?
What if I have abnormal liver tests?
What is the dose for adults?
What is the dose for children?
Can Cresemba cause any serious side effects?
What should I do if I think I have a side effect?
How should I store Cresemba?
What are the common side effects of isavuconazonium?
Does isavuconazonium interact with other medications?
What drug class is isavuconazonium?
What pregnancy or breastfeeding source fields are listed for isavuconazonium?
Related Medications in Azole Antifungal
Other drugs grouped near isavuconazonium - same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with isavuconazonium →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with isavuconazonium →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with isavuconazonium →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with isavuconazonium →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with isavuconazonium →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for isavuconazonium: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 3,219.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 20.94%.
- dronabinol Δ 0.02 pts · 7,819 reports · Cannabinoid Antiemetic 20.96%death share
- tetrabenazine Δ 0.17 pts · 7,235 reports · VMAT2 Inhibitor 21.11%death share
- carisoprodol Δ 0.26 pts · 18,851 reports · Centrally Acting Muscle Relaxant 21.20%death share
- pyridoxine Δ 0.40 pts · 2,439 reports · Vitamin B6 Supplement 20.54%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on isavuconazonium
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for isavuconazonium
The FDA label for isavuconazonium (sold under brand names such as Cresemba) classifies it as a prescription-only medication in the Azole Antifungal class. Cresemba treats invasive aspergillosis and invasive mucormycosis. Official labeling lists 11 commonly reported side effects, including Nausea, Vomiting, Diarrhea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 3,219 voluntary reports. The database also lists 9 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: April 25, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages